TY - CHAP
T1 - Rational therapy for renal cell carcinoma based on its genetic targets
AU - Messer, Jamie
AU - Drabick, Joseph
AU - Kaag, Matthew
PY - 2013
Y1 - 2013
N2 - Renal cell carcinoma (RCC) is not a single entity, rather it is a term defining a group of histologically distinct tumors arising in the renal parenchyma. Each histologic subtype is clinically and genetically unique. It is our understanding of the genetic basis for these cancers that has led to the variety of targeted systemic therapies now available in RCC. This review will cover the basic tumor biology behind each histology, as well as the associated therapeutic targets identified thus far. Mechanisms and associated side effects of the currently available drugs will be examined. Completed clinical trials will be discussed, leading into the rationale behind currently active trials, and future directions for drug development.
AB - Renal cell carcinoma (RCC) is not a single entity, rather it is a term defining a group of histologically distinct tumors arising in the renal parenchyma. Each histologic subtype is clinically and genetically unique. It is our understanding of the genetic basis for these cancers that has led to the variety of targeted systemic therapies now available in RCC. This review will cover the basic tumor biology behind each histology, as well as the associated therapeutic targets identified thus far. Mechanisms and associated side effects of the currently available drugs will be examined. Completed clinical trials will be discussed, leading into the rationale behind currently active trials, and future directions for drug development.
UR - http://www.scopus.com/inward/record.url?scp=84873602698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873602698&partnerID=8YFLogxK
U2 - 10.1007/978-1-4614-6176-0_13
DO - 10.1007/978-1-4614-6176-0_13
M3 - Chapter
C2 - 23288645
AN - SCOPUS:84873602698
SN - 9781461461753
T3 - Advances in Experimental Medicine and Biology
SP - 291
EP - 308
BT - Impact of Genetic Targets on Cancer Therapy
PB - Springer Science and Business Media, LLC
ER -